GSK extends presence in South Korea with Dong-A stake

Published: 12-May-2010
Finance

Firms will co-promote primary care products in Korean market


GlaxoSmithKline (GSK) has paid £74m to take a 9.9% share in Dong-A Pharmaceuticals, the leading pharmaceutical and otc company in South Korea.

The two firms will co-promote selected GSK and Dong-A pharmaceutical products for use in primary care and share the profit generated from sales. Additional synergies will be explored to strengthen their positions in the Korean pharmaceutical market.

Dong-A has a portfolio of proprietary and generic pharmaceutical products and consumer healthcare brands. Sales in 2009 were £414m.

‘With Dong-A’s market-leading position and expertise in Korea, this alliance presents a significant opportunity for GSK to extend its commercial footprint and build operational scale in this fast growing Asian market,’ said Christophe Weber, senior vice president and regional director of Asia Pacific for GSK.

Won-Bae Kim, president of Dong-A, added: ‘This collaboration is expected to improve our market competitiveness in the fast changing domestic and global pharmaceutical markets.’

  • Companies:
  • GlaxoSmithKline
  • Dong-A Pharmaceutical Co
See more

You may also like

Manufacturing

GSK bolsters its US drug manufacturing capabilities with $800m investment

Read more
The expansion will double the size and capacity of its Marietta site, supporting the manufacture of sterile liquid vaccines and production for clinical trials

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  2. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  5. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

GSK bolsters its US drug manufacturing capabilities with $800m investment

The expansion will double the size and capacity of its Marietta site, supporting the manufacture of sterile liquid vaccines and production for clinical trials
Manufacturing

Wood wins significant $50m US Life Sciences project with GSK

Wood’s three-year contract will support GSK’s production of innovative specialty medicines for the US and globally as part of GSK’s plan to develop the site
Finance

Sareum notes completion of Sierra Oncology’s acquisition by GSK

Sareum Holdings, the specialist drug development company, notes that GSK has completed its acquisition of Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), for $1.9 billion in cash
Finance

GSK shingles vaccine available in the UK

The UK launch of the vaccine follows "unanticipated demand," the company says
Finance

Medicines Manufacturing Innovation Centre completes construction

The internal fit out of the facility is planned to be completed in early 2022
Finance

Sanofi and GSK in discussions with EU to supply COVID-19 vaccine

Sanofi and GSK in advanced discussions with the European Union to supply up to 300 million doses of COVID-19 vaccine
Ingredients

Sanofi and GSK team up on adjuvanted COVID-19 vaccine

The companies have entered into a Material Transfer Agreement to enable them to start working together immediately
Subscribe now